Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan-Dec:28:10760296221088576.
doi: 10.1177/10760296221088576.

The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System

R Arreola-Diaz  1 , A Majluf-Cruz  2 , L E Sanchez-Torres  1 , J Hernandez-Juarez  3
Affiliations
Review

The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System

R Arreola-Diaz et al. Clin Appl Thromb Hemost. 2022 Jan-Dec.

Abstract

The antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by a hypercoagulability associated to vascular thrombosis and/or obstetric morbidity, is caused by the presence of antiphospholipid antibodies such as lupus anticoagulant, anti-β-2-glycoprotein 1, and/or anticardiolipin antibodies. In the obstetrical APS, antiphospholipid antibodies induce the production of proinflammatory cytokines and tissue factor by placental tissues and recruited neutrophils. Moreover, antiphospholipid antibodies activate the complement system which, in turn, induces a positive feedback leading to recruitment of neutrophils as well as activation of the placenta. Activation of these cells triggers myometrial contractions and cervical ripening provoking the induction of labor. In thrombotic and obstetrical APS, antiphospholipid antibodies activate endothelial cells, platelets, and neutrophils and they may alter the multimeric pattern and concentration of von Willebrand factor, increase the concentration of thrombospondin 1, reduce the inactivation of factor XI by antithrombin, increase the activation of factor XII, and reduce the activity of tissue plasminogen activator with the subsequent production of plasmin. All these effects result in less permeable clots, denser, thinner, and with more branched fibrin fibers which are more difficult to lysate. As a consequence, thrombosis, the defining clinical criterion of APS, complicates the clinical course of the patient.

Keywords: antiphospholipid syndrome; autoantibodies; autoimmunity; miscarriage; thrombosis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Physiological roles of β2GPI. β2GPI has several functions. It may act as an opsonin leading the clearance of anionic phospholipid composed vesicles as well as a scavenger of LPS. These two effects reduce the inflammatory response. On the other hand, β2GPI is a modulator of the complement system, angiogenesis, and hemostasis.
Figure 2.
Figure 2.
Pathophysiology of obstetric APS. aPLs may directly activate the placenta through the interaction of anti-β2GPI with β2GPI and/or annexin A2, leading to the production of pro-inflammatory cytokines and chemokines (primarily IL-8) which may recruit neutrophils. In turn, these cells are activated by aPLs which may induce the generation of NETs and the consequent activation of the placenta by the coupling to TLR2/4. Finally, activation and lipid peroxidation of the placenta may trigger myometrial and uterine contraction, cervical ripening, membrane rupture, and labor induction.
Figure 3.
Figure 3.
Histones can activate cells through the engagement of TLR2/4. aPLs may trigger the release of NETs composed mainly of histones, neutrophil elastase, and myeloperoxidase. These biochemical compounds are recognized by TLR2/4 and, when complexed, they may trigger the activation of the placenta, endothelium, and platelets, among other cells. Furthermore, these constituents may prolong the activated thromboplastin time test through the direct inhibition of the contact phase activation. In addition, they can enhance the thrombin rate generation and the endogenous thrombin potential.
Figure 4.
Figure 4.
Physiopathology of APS. aPls may activate different cells. In monocytes, aPLs binds to β2GPI triggering the production of TF, cytokines, and proinflammatory chemokines. In endothelial cells, aPLs induce the production of chemokines, proinflammatory cytokines, TF, ROS, and ET-1 and the consumption of NO. On the other hand, aPLs increase the platelet sensitivity to its agonists while increasing the production of TxA2. The effects of aPLs on hemostasis and fibrinolysis range from inhibition of tPA activity and inhibition of FXII-mediated fibrinolysis to inhibition of FXI inactivation by antithrombin as well as increased FXIII synthesis. Indirectly, aPLs also activate cells involved in APS through the activation of neutrophils and the release of NETs. In NETs, DNA and elastases are recognized by TLR2/4, leading to activation of the placenta, endothelium, and platelets.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stachowicz A, Zabczyk M, Natorska J, et al. Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism. Sci Rep. 2018;8(1):17301. doi:10.1038/s41598-018-35034-x - DOI - PMC - PubMed
    1. Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev. 2017;31(6):406‐417. doi:10.1016/j.blre.2017.07.006 - DOI - PMC - PubMed
    1. Levy RA, Gómez-Puerta JA, Cervera R. History, classification, and subsets of the antiphospholipid syndrome. In: Cervera R, Espinosa G, Khamashta M, eds. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. 2nd ed. Elsevier; 2017:1‐16.
    1. Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease. Ther Adv Musculoskelet Dis. 2013;5(6):305‐314. doi:10.1177/1759720X13502919 - DOI - PMC - PubMed
    1. Willis R, Gonzalez EB, Brasier AR. The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome. Curr Rheumatol Rep. 2015;17(3):16. doi:10.1007/s11926-014-0485-9 - DOI - PubMed

Substances